**AMENDMENTS TO THE CLAIMS** 

1. (Currently Amended) A method for forming an endovascular occlusion comprising the step

of controlling injection of a purified alginate liquid and injection of a calcium chloride solution to a

targeted area within a vascular system, wherein the injection of the purified alginate liquid and

injection of the calcium chloride solution are at variable injection rates, either within an injection

stage or across injection stages, and wherein the purified liquid alginate is of a molecular weight

from about 65,000 to about 200,000.

2.-4. (Canceled).

5. (Canceled)

6. (Original) The method according to claim 1, wherein the injection flow rate of the

calcium chloride solution is variable during injection.

7. (Original) The method according to claim 1, wherein injection of the calcium chloride

solution occurs at staged intervals.

8. (Canceled)

9. (Canceled)

10. (Original) The method according to claim 1, wherein the injection flow rate of the

alginate liquid solution is variable during injection.

11. (Original) The method according to claim 1, wherein injection of the alginate liquid

solution occurs at staged intervals.

12. (Original) The method according to claim 1, wherein the injection flow rates of the

alginate liquid and the calcium chloride solution are about equal during injection.

After Final Office Action of May 23, 2007

13. (Original) The method according to claim 1, wherein the injection flow rates of the

Docket No.: 65306-0092

alginate liquid and the calcium chloride solution are different during injection.

14. (Original) The method according to claim 1, wherein injection of the alginate liquid and

injection of the calcium chloride solution occur at staged intervals.

15. (Original) The method according to claim 1, wherein one or more agents are added to

the alginate liquid during the controlled injection.

16. (Original) The method according to claim 15, wherein the one or more agents are

selected from the group consisting of therapeutic drugs, radioactive or contrast agents, growth

enhancers or inhibitors, or any combination thereof.

17. (Currently Amended) A method for forming an endovascular occlusion comprising the steps

of:

a. Providing a catheter comprised of at least two lumens, and

b. Forming a calcium alginate polymer in a targeted area within a vascular system by

controlling injection of a purified alginate liquid and injection of a calcium chloride solution to the

targeted area through the catheter, wherein the polymer is formed external to the catheter within the

target site and wherein injection of the purified alginate liquid and injection of the calcium chloride

solution are at variable injection rates, either within an injection stage or across injection stages, and

wherein the purified alginate liquid is of molecular weight from about 65,000 to about 200,000.

18-20. (Canceled).

21. (Original) The method according to claim 17, wherein the at least two lumens are

concentric.

22. (Canceled).

23. (Currently Amended) A method for forming an endovascular occlusion comprising the steps

of:

Amendment dated October 31, 2007

After Final Office Action of May 23, 2007

a. providing at least one assist device to a targeted area in a vascular system, and

b. controlling injection of a purified alginate liquid and injection of a calcium chloride

solution to the targeted area, wherein injection of the alginate liquid and injection of the calcium

chloride solution are at variable injection rates, either within an injection stage or across injection

stages, and wherein the purified alginate liquid is of molecular weight from about 65,000 to about

200,000.

24. (Original) The method according to claim 23, wherein the at least one assist device

comprises a coil, a stent, a balloon, or any combination thereof.

25. (Currently amended) A method for forming an endovascular occlusion comprising the steps

of:

a. providing an ion-permeable balloon to a targeted area in a vascular system,

b. controlling injection of a purified alginate liquid having a high guluronic acid content

to the targeted area; and

c. controlling injection of a calcium chloride solution to the targeted area by injecting

the calcium chloride solution into the ion-permeable balloon, wherein the purified alginate liquid is

of molecular weight from about 65,000 to about 200,000.

26. (Currently amended) A method for forming an endovascular occlusion comprising the steps

of:

a. providing a balloon to a targeted area in a vascular system, and

b. controlling injection of a purified alginate liquid having a high guluronic acid content

and injection of a calcium chloride solution to the targeted area,

wherein the alginate liquid and the calcium chloride solution are injected

asynchronously, and wherein the balloon has one or more built-in catheters, and wherein the

purified alginate liquid is of molecular weight from about 65,000 to about 200,000...

- 27. (Currently Amended) A method for forming an endovascular occlusion comprising the steps of:
  - providing at least one pre-coated coil to a targeted area in a vascular system, and a.

Docket No.: 65306-0092

b. controlling injection of a purified alginate liquid having a high guluronic acid content and injection of a calcium chloride solution to the targeted area,

wherein injection of the alginate liquid and injection of the calcium chloride solution are at variable injection rates, either within an injection stage or across injection stages, and wherein the purified alginate liquid is of molecular weight from about 65,000 to about 200,000.

- 28. (Original) The method according to claim 27, wherein the coil is pre-coated with at least a conformal coating of alginate gel.
- The method according to claim 27, wherein the coil is pre-coated with at least 29. (Original) a conformal coating of unreacted alginate liquid.
- 30. (Original) The method according to claim 27, wherein the coil is pre-coated with at least calcium chloride ions.
- 31. (Original) The method according to claim 27, wherein the coil is pre-coated with collagen, permeable gel, or polymer material.
- 32. The method according to claim 28, wherein the coil is modified by ion (Original) implantation before placement of the coil in the targeted area.
- 33. (Canceled).
- 34. (Canceled).
- 35. (Previously Presented) The method according to claim 1, wherein the purified alginate liquid has a viscosity less than 25 cP.
- 36. (Canceled).

Application No. 10/738,317 Amendment dated October 31, 2007

After Final Office Action of May 23, 2007

37. (Previously presented) The method according to claim 17, wherein the purified

alginate liquid has a viscosity less than 25 cP.

38. (Previously Presented) A method for forming an endovascular occlusion comprising the

steps of:

a. Providing a catheter comprising a microcatheter having a first lumen with a second

Docket No.: 65306-0092

catheter disposed inside the first lumen, the second catheter having a second lumen that is

concentric with the first lumen, the distal end of the second lumen being adjustable with respect to

the distal end of the first lumen; and

b. Forming a calcium alginate polymer in a targeted area within a vascular system by

controlling injection of a purified alginate liquid and injection of a calcium chloride solution to the

targeted area through the catheter, wherein injection of the purified alginate liquid and injection of

the calcium chloride solution are at variable injection rates.

39. (Previously Presented) The method of Claim 38, wherein the distal end of the second

lumen is adjusted with respect to the distal end of the first lumen so that the polymer is formed

external to the catheter within the target site.

40. (Previously Presented) The method according to claim 39, wherein the purified

alginate liquid is of molecular weight from about 65,000 to about 200,000.

41. (Previously Presented) The method according to claim 39, wherein the purified alginate

liquid has a viscosity less than 25 cP.

42. (Previously Presented) The method of Claim 38, wherein the distal end of the second lumen

is adjusted with respect to the distal end of the first lumen so that the polymer begins to form within

the first lumen.

43. (Previously Presented) The method according to claim 42, wherein the purified alginate

liquid is of molecular weight from about 65,000 to about 200,000.

Application No. 10/738,317 Amendment dated October 31, 2007 After Final Office Action of May 23, 2007

44. (Previously Presented) The method according to claim 42, wherein the purified alginate liquid has a viscosity less than 25 cP.

Docket No.: 65306-0092